EUVIMEDEUVIMED entdecken
ValidierungsstudieOpen Access · CC BY 4.0

Validation and performance assessment of a commercial anti-peroxidasin antibody

Isabel Brandão, Roberto Silva, Bárbara Gomes, Jorge R Almeida, João Paulo Oliveira, Inês S Alencastre

Histochemistry and Cell Biology · 21.01.2026 · 164 (1)

DOI: 10.1007/s00418-025-02453-7 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift Histochemistry and Cell Biology, online erschienen am 21.01.2026. Verfasst von Isabel Brandão und 5 weiteren Autor:innen. Beteiligte Einrichtung: Instituto de Investigação e Inovação em Saúde, Porto, Portugal. Hauptthemen laut MEDLINE: Antibodies, Extracellular Matrix Proteins, Peroxidase. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundação para a Ciência e a Tecnologia, Universidade do Porto.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Peroxidasin (PXDN) is a multi-domain heme peroxidase that catalyzes sulfilimine cross-links in type IV collagen, a reaction essential for basement membrane stability. In addition to its structural role, PXDN has been implicated in oxidative stress regulation, fibrosis, and tumorigenesis. Antibody-based detection is critical for defining PXDN expression and localization, yet few commercial reagents have been rigorously validated, limiting reproducibility. Here, we assessed the specificity and performance of a commercially available anti-PXDN antibody (Abbexa, abx101906) in immunohistochemistry and immunocytochemistry applications. Validation was performed in formalin-fixed, paraffin-embedded human kidney tissue and in a primary kidney fibroblast line under PXDN silencing and overexpression conditions. The antibody yielded reproducible labeling patterns and demonstrated specificity across cellular contexts. These findings establish abx101906 as a reliable tool for immunofluorescence-based detection of PXDN. This validation provides a foundation for future studies of PXDN biology in kidney development, disease, and potential therapeutic targeting.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AntibodiesExtracellular Matrix ProteinsPeroxidaseHumansPeroxidasinImmunohistochemistryKidney

Stichwörter der Autor:innen

Anti-PXDN antibodyHuman kidney biopsiesImmunofluorescenceKidney fibroblasts

Substanzen

PeroxidasinAntibodiesExtracellular Matrix ProteinsPXDN protein, humanPeroxidase

Autor:innen und Institutionen

  • Instituto de Investigação e Inovação em Saúde, Porto, Portugal.
  • Universidade do Porto - Instituto de Ciências Biomédicas Abel Salazar, Porto, Portugal.
  • Unidade Local de Saúde de São João, Porto, Portugal.
  • Universidade do Porto - Faculdade de Medicina, Porto, Portugal.
  • Universidade do Porto - Faculdade de Medicina, Porto, Portugal. ialencastre@med.up.pt.
  • RISE-Health, Porto, Portugal. ialencastre@med.up.pt.

Förderung

  • Fundação para a Ciência e a Tecnologia
  • Universidade do Porto

Zitieren

APA

Brandão, I., Silva, R., Gomes, B., Almeida, J. R., Oliveira, J. P., & Alencastre, I. S. (2026). Validation and performance assessment of a commercial anti-peroxidasin antibody. Histochemistry and Cell Biology, 164(1). https://doi.org/10.1007/s00418-025-02453-7

Vancouver

Brandão I, Silva R, Gomes B, Almeida JR, Oliveira JP, Alencastre IS. Validation and performance assessment of a commercial anti-peroxidasin antibody. Histochemistry and Cell Biology. 2026;164(1). doi:10.1007/s00418-025-02453-7

BibTeX
@article{Brando2026,
  author = {Brandão, Isabel and Silva, Roberto and Gomes, Bárbara and Almeida, Jorge R and Oliveira, João Paulo and Alencastre, Inês S},
  title = {Validation and performance assessment of a commercial anti-peroxidasin antibody},
  journal = {Histochemistry and Cell Biology},
  year = {2026},
  volume = {164},
  number = {1},
  doi = {10.1007/s00418-025-02453-7}
}
Kostenlos starten →